hVIVO plc (LON:HVO), a leading provider of human challenge trial services, has made headlines with the announcement of its largest standalone hLAB contract to date. The £3.2 million project showcases the company’s growing capabilities and highlights its recent advancements in laboratory capacity.
The agreement involves hLAB, hVIVO’s specialist virology and immunology laboratory, providing exclusive services for a US-based biotechnology client. Notably, this contract includes virology and immunology lab support for an international, multi-site Phase 2 clinical study of an influenza drug candidate. With work on the study commencing immediately, hLAB is poised to deliver across the 5,000 trial participants recruited globally.
A Milestone Achievement for hVIVO
This £3.2 million deal builds on an earlier £0.5 million commitment, making it a landmark achievement for hVIVO. It demonstrates the success of the company’s standalone laboratory services, which were launched in September 2024. The majority of the project revenue is expected to be recognised in 2025, with the remaining portion following in 2026.
